Search clinical trials for: PF-07264660 subcutaneous multiple ascending dose

Total 36 results

Pfizer

Active, not recruiting

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Healthy

United States
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1837

Healthy

Belgium
GEN İlaç ve Sağlık Ürünleri A.Ş.
Sulfateq B.V.

Recruiting

A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

Healthy Subjects

Turkey
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1972

Healthy

Belgium
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 (CHF6001Ext)

Chronic Obstructive Pulmonary Disease

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Enterome
Quotient Clinical

Completed

First-in-Human Single and Multiple Dose of EB8018

Healthy Volunteers

United Kingdom
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1690

Healthy

Belgium
Hanmi Pharmaceutical Company Limited

Completed

Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers

Rheumatoid Arthritis

Netherlands
Nanjing Immunophage Biotech Co., Ltd
Novotech (Australia) Pty Limited

Not yet recruiting

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Atopic Dermatitis

Australia
7 Hills Pharma, LLC
Frontage Clinical Services, Inc.

Completed

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

Solid Tumor

United States
OliPass Corporation

Completed

OLP-1002 is Being Studied in the Treatment of Pain.

Pain

United Kingdom
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1205

Healthy

Belgium
Jiangsu Sinorda Biomedicine Co., Ltd

Completed

Single-dose and Multiple-dose X842 Phase 1 Study

Healthy Volunteers

China
Stoke Therapeutics, Inc

Completed

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

Dravet Syndrome

United States
Nexel Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of NP-011 in Healthy Volunteers

Myocardial Infarction

Australia
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers

Bladder Cancer

Australia
Future Medicine

Completed

A SAD, MAD, and FE Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of FM101 in Healthy Volunteers

Healthy Subjects

Netherlands
Société des Produits Nestlé (SPN)

Completed

Oral CDX-7108 in Healthy Adults and EPI Subjects

Exocrine Pancreatic Insufficiency

Australia, New Zealand
Ornovi, Inc.

Withdrawn

A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects

Alopecia Areata

Australia
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

Hepatitis B | HBV

Korea, Republic of, United States, Canada, Australia, New Zealand
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

Hepatitis C

United States, Puerto Rico
AstraZeneca

Completed

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

Healthy Volunteers | Tolerability | Safety

United Kingdom
Cinclus Pharma AG

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study

Healthy Volunteers

Sweden
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Hepatitis B

Korea, Republic of, United States, Canada, Australia, New Zealand
Second Affiliated Hospital, School of Medicine,...

Recruiting

Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study

Hepatectomy | Stereotactic Body Radiotherapy | Centrally Located Hepatocellular Carcinoma

China
Immunocore Ltd

Recruiting

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

Hepatitis B, Chronic

Hong Kong, Korea, Republic of, Taiwan, Denmark, United States, Australia, Romania, United Kingdom, Spain
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
ImmuneMed, Inc.

Completed

Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)

Healthy Volunteers

Australia
Castilla-La Mancha Health Service
Universidad de Córdoba; University of Castilla-La Mancha

Completed

Continuous Subcutaneous Insulin Infusion Versus Multiple Dose Insulin Injections in Routine Clinical Practice (real-ECIMI)

Type 1 Diabetes Mellitus

Spain
University Hospital Schleswig-Holstein

Recruiting

Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes

Safety Issues | Pharmacokinetic

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States

3

Subscribe